MA30407B1 - Composes a base de benzoxazole et de benzothiazole 6-0 substitues et procedes d'inhibition de signalisation csf-1r - Google Patents
Composes a base de benzoxazole et de benzothiazole 6-0 substitues et procedes d'inhibition de signalisation csf-1rInfo
- Publication number
- MA30407B1 MA30407B1 MA31372A MA31372A MA30407B1 MA 30407 B1 MA30407 B1 MA 30407B1 MA 31372 A MA31372 A MA 31372A MA 31372 A MA31372 A MA 31372A MA 30407 B1 MA30407 B1 MA 30407B1
- Authority
- MA
- Morocco
- Prior art keywords
- benzoxazole
- compounds
- inhibition
- signaling
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
ON DÉCRIT LES COMPOSÉS À BASE DE BENZOXAZOLE ET DE BENZOTHIAZOLE ET LES STÉRÉOISOMÈRES, LES TAUTOMÈRES, LES SOLVATES, LES OXYDES, LES ESTERS ET LEURS PROMÉDICAMENTS AINSI QUE LEURS SELS ACCEPTABLES SUR LE PLAN PHARMACEUTIQUE. ON DÉCRIT AUSSI LES COMPOSITIONS DES COMPOSÉS, SOIT SEULS SOIT EN COMBINAISON AVEC AU MOINS UN AGENT THÉRAPEUTIQUE SUPPLÉMENTAIRE, AVEC UN EXCIPIENT ACCEPTABLE SUR LE PLAN PHARMACEUTIQUE, ET LES UTILISATIONS DES COMPOSÉS, SOIT SEULS SOIT EN COMBINAISON AVEC AU MOINS UN AUTRE AGENT THÉRAPEUTIQUE SUPPLÉMENTAIRE. LES MODES DE RÉALISATION SONT UTILES POUR L'INHIBITION DE LA PROLIFÉRATION CELLULAIRE, L'INHIBITION DE LA CROISSANCE ET/OU DE LA MÉTASTASE DE TUMEURS, LE TRAITEMENT OU LA PRÉVENTION DU CANCER, LE TRAITEMENT OU LA PRÉVENTION DE MALADIES OSSEUSES DÉGÉNÉRATIVES TELLES QUE L'ARTHRITE RHUMATOÏDE ET/OU L'INHIBITION DE MOLÉCULES TELLES QUE LA CSF-1R.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US79351706P | 2006-04-19 | 2006-04-19 | |
US89385707P | 2007-03-08 | 2007-03-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA30407B1 true MA30407B1 (fr) | 2009-05-04 |
Family
ID=38610468
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA31372A MA30407B1 (fr) | 2006-04-19 | 2008-11-10 | Composes a base de benzoxazole et de benzothiazole 6-0 substitues et procedes d'inhibition de signalisation csf-1r |
Country Status (30)
Country | Link |
---|---|
US (3) | US7553854B2 (fr) |
EP (1) | EP2010528B1 (fr) |
JP (1) | JP5328640B2 (fr) |
KR (1) | KR101464385B1 (fr) |
AR (1) | AR060545A1 (fr) |
AU (1) | AU2007237904B2 (fr) |
BR (1) | BRPI0710540B1 (fr) |
CA (1) | CA2649288C (fr) |
CR (1) | CR10365A (fr) |
CY (1) | CY1119679T1 (fr) |
DK (1) | DK2010528T3 (fr) |
EA (1) | EA018917B1 (fr) |
EC (1) | ECSP088830A (fr) |
ES (1) | ES2654847T3 (fr) |
HR (1) | HRP20171924T1 (fr) |
HU (1) | HUE035654T2 (fr) |
IL (1) | IL194662A0 (fr) |
LT (1) | LT2010528T (fr) |
MA (1) | MA30407B1 (fr) |
MX (1) | MX2008013427A (fr) |
NO (1) | NO20084800L (fr) |
PE (1) | PE20080359A1 (fr) |
PL (1) | PL2010528T3 (fr) |
PT (1) | PT2010528T (fr) |
RS (1) | RS56600B1 (fr) |
SI (1) | SI2010528T1 (fr) |
SM (1) | SMP200800063B (fr) |
TN (1) | TNSN08406A1 (fr) |
TW (1) | TW200813039A (fr) |
WO (1) | WO2007121484A2 (fr) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2480638C (fr) * | 2002-03-29 | 2013-02-12 | Chiron Corporation | Benzazoles substitues et leur utilisation en tant qu'inhibiteurs de la kinase raf |
EP2010528B1 (fr) * | 2006-04-19 | 2017-10-04 | Novartis AG | Composés à base de benzoxazole et de benzothiazole 6-0 substitués et procédés d'inhibition de signalisation csf-1r |
CA2671121C (fr) * | 2006-12-06 | 2016-06-07 | University Of Central Florida Research Foundation, Inc. | Inhibiteur de stat3 ayant une activite anticancereuse et procedes associes |
EP2152700B1 (fr) * | 2007-05-21 | 2013-12-11 | Novartis AG | Inhibiteurs du csf-1r, compositions et procédés d'utilisation |
JP5352476B2 (ja) | 2007-06-05 | 2013-11-27 | 武田薬品工業株式会社 | キナーゼ阻害剤としての二環式複素環化合物 |
US8324395B2 (en) | 2007-08-23 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
CN101801379A (zh) * | 2007-10-18 | 2010-08-11 | 诺瓦提斯公司 | 治疗癌症和骨疾病的csf-1r抑制剂 |
US20110009421A1 (en) * | 2008-02-27 | 2011-01-13 | Takeda Pharmaceutical Company Limited | Compound having 6-membered aromatic ring |
US8697874B2 (en) | 2008-12-01 | 2014-04-15 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
JO3101B1 (ar) | 2008-12-02 | 2017-09-20 | Takeda Pharmaceuticals Co | مشتقات بنزوثيازول كعوامل مضادة للسرطان |
WO2011133661A2 (fr) * | 2010-04-21 | 2011-10-27 | Research Development Foundation | Méthodes et compositions associées aux neurones dopaminergiques |
AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
EP2560488B1 (fr) | 2010-04-23 | 2015-10-28 | Cytokinetics, Inc. | Aminopyridines et aminotriazines, leurs compositions et leurs procédés d'utilisation |
AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
EP2661434A4 (fr) * | 2011-01-06 | 2014-07-09 | Beta Pharma Canada Inc | Nouvelles urées pour le traitement et la prévention du cancer |
US8759380B2 (en) | 2011-04-22 | 2014-06-24 | Cytokinetics, Inc. | Certain heterocycles, compositions thereof, and methods for their use |
WO2012151541A1 (fr) * | 2011-05-05 | 2012-11-08 | Novartis Ag | Inhibiteurs de csf-1r pour le traitement de tumeurs cérébrales |
HUE032754T2 (en) * | 2011-05-05 | 2017-10-30 | Novartis Ag | CSF-1R inhibitors for the treatment of brain tumors |
MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
TWI716362B (zh) | 2014-10-14 | 2021-01-21 | 瑞士商諾華公司 | 針對pd-l1之抗體分子及其用途 |
RU2731055C2 (ru) * | 2014-12-03 | 2020-08-28 | Дженентек, Инк. | Конъюгаты антитела к staphylococcus aureus с рифамицином и их применение |
SG11201704792UA (en) | 2014-12-22 | 2017-07-28 | Five Prime Therapeutics Inc | Anti-csf1r antibodies for treating pvns |
CN112028825A (zh) * | 2015-04-07 | 2020-12-04 | 广东众生睿创生物科技有限公司 | 酪氨酸激酶抑制剂及包含该酪氨酸激酶抑制剂的药物组合物 |
US10722517B2 (en) | 2015-05-08 | 2020-07-28 | Memorial Sloan Kettering Cancer Center | Compositions and methods for treatment of glioma |
US20180207273A1 (en) | 2015-07-29 | 2018-07-26 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
PT3317301T (pt) | 2015-07-29 | 2021-07-09 | Novartis Ag | Terapias de associação compreendendo moléculas de anticorpo contra lag-3 |
JP2019503349A (ja) | 2015-12-17 | 2019-02-07 | ノバルティス アーゲー | Pd−1に対する抗体分子およびその使用 |
CA3014269A1 (fr) | 2016-02-11 | 2017-08-17 | Invictus Oncology Pvt. Ltd. | Inhibiteurs de signalisation cellulaire, leurs formules et leurs procedes |
SG10202009423QA (en) | 2016-03-28 | 2020-11-27 | Incyte Corp | Pyrrolotriazine compounds as tam inhibitors |
WO2018071348A1 (fr) * | 2016-10-10 | 2018-04-19 | Development Center For Biotechnology | Composés de quinoxaline en tant qu'inhibiteurs de tyrosine kinase du récepteur de type iii |
CA3039764A1 (fr) * | 2016-10-14 | 2018-04-19 | Novartis Ag | Formes cristallines de 4- (2- ((1r,2r)-2-hydroxycyclohexylamino) benzothiazol-6-yloxy)-n-methylpicolinamide |
RU2019114205A (ru) * | 2016-10-14 | 2020-11-16 | Новартис Аг | Способы лечения глазного заболевания с применением ингибиторов csf-1r |
AU2017355603A1 (en) | 2016-11-04 | 2019-06-20 | Auckland Uniservices Limited | Tricyclic heterocyclic derivatives and uses thereof |
TW201829402A (zh) * | 2016-12-23 | 2018-08-16 | 美商提薩羅有限公司 | 群落刺激因子1受體 (csf-1r)之小分子抑制劑及其用途 |
WO2018146641A1 (fr) * | 2017-02-11 | 2018-08-16 | Invictus Oncology Pvt. Ltd. | Nouveaux inhibiteurs de signalisation cellulaire |
EP3600311B1 (fr) | 2017-03-28 | 2024-05-15 | Novartis AG | Méthodes novatrices pour le traitement de la sclérose en plaques |
UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
US20200172628A1 (en) | 2017-06-22 | 2020-06-04 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
EA202090104A1 (ru) | 2017-06-22 | 2020-04-09 | Новартис Аг | Молекулы антител к cd73 и пути их применения |
WO2019099838A1 (fr) | 2017-11-16 | 2019-05-23 | Novartis Ag | Polythérapies |
US11324729B2 (en) | 2017-12-07 | 2022-05-10 | The Regents Of The University Of Michigan | NSD family inhibitors and methods of treatment therewith |
TW202015726A (zh) | 2018-05-30 | 2020-05-01 | 瑞士商諾華公司 | Entpd2抗體、組合療法、及使用該等抗體和組合療法之方法 |
US20210214459A1 (en) | 2018-05-31 | 2021-07-15 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
US11241438B2 (en) | 2018-06-29 | 2022-02-08 | Incyte Corporation | Formulations of an AXL/MER inhibitor |
AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
CA3123511A1 (fr) | 2018-12-20 | 2020-06-25 | Novartis Ag | Schema posologique et combinaison pharmaceutique comprenant des derives de 3-(1-oxoisoindoline-2-yl) piperidine-2,6-dione |
WO2020128637A1 (fr) | 2018-12-21 | 2020-06-25 | Novartis Ag | UTILISATION D'ANTICORPS DE LIAISON À IL-1β DANS LE TRAITEMENT D'UN CANCER MSI-H |
EP3898674A1 (fr) | 2018-12-21 | 2021-10-27 | Novartis AG | Utilisation d'anticorps se liant à il-1bêta |
EP3897613A1 (fr) | 2018-12-21 | 2021-10-27 | Novartis AG | Utilisation d'anticorps de liaison à il-1bêta |
US20220040324A1 (en) | 2018-12-21 | 2022-02-10 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and kinase inhibitor |
CA3123519A1 (fr) | 2019-02-15 | 2020-08-20 | Novartis Ag | Derives de 3-(1-oxoisoindoline-2-yl)piperidine-2,6-dione substitues et leurs utilisations |
WO2020165833A1 (fr) | 2019-02-15 | 2020-08-20 | Novartis Ag | Dérivés de 3-(1-oxo-5-(pipéridin-4-yl)isoindolin-2-yl)pipéridine-2,6-dione et leurs utilisations |
CN114502590A (zh) | 2019-09-18 | 2022-05-13 | 诺华股份有限公司 | Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法 |
CN115175937A (zh) | 2019-12-20 | 2022-10-11 | 诺华股份有限公司 | 用于治疗骨髓纤维化和骨髓增生异常综合征的抗TIM-3抗体MBG453和抗TGF-β抗体NIS793与或不与地西他滨或抗PD-1抗体斯巴达珠单抗的组合 |
BR112022021105A2 (pt) | 2020-04-21 | 2022-11-29 | Novartis Ag | Regime de dosagem para tratar uma doença modulada por csf-1r |
CA3181537A1 (fr) | 2020-05-06 | 2021-11-11 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles et azabenzimidazoles en tant qu'inhibiteurs de jak2 |
JP2023531676A (ja) | 2020-06-23 | 2023-07-25 | ノバルティス アーゲー | 3-(1-オキソイソインドリン-2-イル)ピぺリジン-2,6-ジオン誘導体を含む投与レジメン |
WO2022029573A1 (fr) | 2020-08-03 | 2022-02-10 | Novartis Ag | Dérivés de 3-(1-oxoisoindolin-2-yl)pipéridine-2,6-dione substitués par hétéroaryle et leurs utilisations |
TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途 |
AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
WO2023009712A1 (fr) * | 2021-07-29 | 2023-02-02 | Ajax Therapeutics, Inc. | Hétéroaryloxy thiazolo azines en tant qu'inhibiteurs de jak2 |
WO2023086319A1 (fr) | 2021-11-09 | 2023-05-19 | Ajax Therapeutics, Inc. | 6-hetero-aryloxy-benzimidazoles et azabenzimidazoles en tant qu'inhibiteurs de jak2 |
WO2024095118A1 (fr) | 2022-10-31 | 2024-05-10 | Novartis Ag | Schéma posologique d'un inhibiteur de csf-1r destiné à être utilisé dans le traitement de la sclérose latérale amyotrophique |
Family Cites Families (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
US4231938A (en) | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
US4294926A (en) | 1979-06-15 | 1981-10-13 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
US4319039A (en) | 1979-06-15 | 1982-03-09 | Merck & Co., Inc. | Preparation of ammonium salt of hypocholesteremic fermentation product |
US4444784A (en) | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
DK149080C (da) | 1980-06-06 | 1986-07-28 | Sankyo Co | Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre |
JPS5889191A (ja) | 1981-11-20 | 1983-05-27 | Sankyo Co Ltd | 3−ヒドロキシ−ml−236b誘導体の製造法 |
US5354772A (en) | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
WO1984002131A1 (fr) | 1982-11-22 | 1984-06-07 | Sandoz Ag | Produits analogues de mevalolactone et leurs derives, leurs procedes de production, compositions pharmaceutiques les contenant ainsi que leur utilisation en tant que produits pharmaceutiques |
US4911165A (en) | 1983-01-12 | 1990-03-27 | Ethicon, Inc. | Pliabilized polypropylene surgical filaments |
US4873346A (en) | 1985-09-20 | 1989-10-10 | The Upjohn Company | Substituted benzothiazoles, benzimidazoles, and benzoxazoles |
US4681893A (en) | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
EP0261459A3 (fr) | 1986-09-09 | 1988-05-11 | Nihon Tokushu Noyaku Seizo K.K. | N-benzothiazolylamides |
US4782084A (en) | 1987-06-29 | 1988-11-01 | Merck & Co., Inc. | HMG-COA reductase inhibitors |
US4885314A (en) | 1987-06-29 | 1989-12-05 | Merck & Co., Inc. | Novel HMG-CoA reductase inhibitors |
US4820850A (en) | 1987-07-10 | 1989-04-11 | Merck & Co., Inc. | Process for α-C-alkylation of the 8-acyl group on mevinolin and analogs thereof |
US5030447A (en) | 1988-03-31 | 1991-07-09 | E. R. Squibb & Sons, Inc. | Pharmaceutical compositions having good stability |
US5180589A (en) | 1988-03-31 | 1993-01-19 | E. R. Squibb & Sons, Inc. | Pravastatin pharmaceuatical compositions having good stability |
US4916239A (en) | 1988-07-19 | 1990-04-10 | Merck & Co., Inc. | Process for the lactonization of mevinic acids and analogs thereof |
US5118853A (en) | 1988-10-13 | 1992-06-02 | Sandoz Ltd. | Processes for the synthesis of 3-disubstituted aminoacroleins |
US5290946A (en) | 1988-10-13 | 1994-03-01 | Sandoz Ltd. | Processes for the synthesis of 3-(substituted indolyl-2-yl)propenaldehydes |
US4929437A (en) | 1989-02-02 | 1990-05-29 | Merck & Co., Inc. | Coenzyme Q10 with HMG-CoA reductase inhibitors |
US5189164A (en) | 1989-05-22 | 1993-02-23 | Sandoz Ltd. | Processes for the synthesis of syn-(E)-3,5-dihydroxy-7-substituted hept-6-enoic and heptanoic acids and derivatives and intermediates thereof |
FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
PH27357A (en) | 1989-09-22 | 1993-06-21 | Fujisawa Pharmaceutical Co | Pyrazole derivatives and pharmaceutical compositions comprising the same |
US5420245A (en) | 1990-04-18 | 1995-05-30 | Board Of Regents, The University Of Texas | Tetrapeptide-based inhibitors of farnesyl transferase |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
HU217629B (hu) | 1991-12-12 | 2000-03-28 | Novartis Ag. | Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására |
NZ257212A (en) | 1992-09-29 | 1996-11-26 | Inhale Therapeutic Syst | Parathyroid hormone formulations comprising a biologically active n-terminal fragment of the hormone |
US5604260A (en) | 1992-12-11 | 1997-02-18 | Merck Frosst Canada Inc. | 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2 |
CA2111902A1 (fr) | 1992-12-21 | 1994-06-22 | Jack Beuford Campbell | Compositions antitumorales et methodes therapeutiques |
CA2152792C (fr) | 1993-01-15 | 2000-02-15 | Stephen R. Bertenshaw | Nouveaux thiophenes 3,4-diaryliques et leurs analogues, utiles comme agents anti-inflammatoires |
WO1994019357A1 (fr) | 1993-02-23 | 1994-09-01 | Merrell Dow Pharmaceuticals Inc. | Inhibiteurs de la transferase farnesyl:proteine utiles comme agents anticancereux |
US5298627A (en) | 1993-03-03 | 1994-03-29 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5409944A (en) | 1993-03-12 | 1995-04-25 | Merck Frosst Canada, Inc. | Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase |
CA2118985A1 (fr) | 1993-04-02 | 1994-10-03 | Dinesh V. Patel | Inhibiteurs heterocycliques de la farnesyl proteine transferase |
EP0763537A3 (fr) | 1993-05-14 | 1997-10-22 | Genentech Inc | Inhibiteurs de la farnesyl-transferase non peptidiques |
US5602098A (en) | 1993-05-18 | 1997-02-11 | University Of Pittsburgh | Inhibition of farnesyltransferase |
US5380738A (en) | 1993-05-21 | 1995-01-10 | Monsanto Company | 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents |
GB9602877D0 (en) | 1996-02-13 | 1996-04-10 | Merck Frosst Canada Inc | 3,4-Diaryl-2-hydroxy-2,5- dihydrofurans as prodrugs to cox-2 inhibitors |
US5474995A (en) | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
US5436265A (en) | 1993-11-12 | 1995-07-25 | Merck Frosst Canada, Inc. | 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents |
US5728830A (en) | 1993-09-22 | 1998-03-17 | Kyowa Hakko Kogyo Co., Ltd. | Farnesyltransferase inhibitor |
IL111235A (en) | 1993-10-15 | 2001-03-19 | Schering Plough Corp | Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them |
TW308594B (fr) | 1993-10-15 | 1997-06-21 | Schering Corp | |
SG43768A1 (en) | 1993-10-15 | 1997-11-14 | Schering Corp | Tricyclic sulfonamide compounds useful for inhibition of g-protein function and for treatment of proliferative dieases |
US5661152A (en) | 1993-10-15 | 1997-08-26 | Schering Corporation | Tricyclic sulfonamide compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
EP0725790B1 (fr) | 1993-10-25 | 2001-04-18 | PARKE DAVIS & COMPANY | Tetra et pentapeptides substitues inhibiteurs de la farnesyl-transferase proteinique |
US5344991A (en) | 1993-10-29 | 1994-09-06 | G.D. Searle & Co. | 1,2 diarylcyclopentenyl compounds for the treatment of inflammation |
DE69417012T2 (de) | 1993-11-04 | 1999-10-07 | Abbott Lab | Cyclobutan-derivate als inhibitoren der squalen-synthetase und der protein-farnesyltransferase |
JP3597863B2 (ja) | 1993-11-05 | 2004-12-08 | ワーナー−ランバート・コンパニー | タンパク質:ファルネシルトランスフェラーゼの置換されたジ‐およびトリペプチド阻害剤 |
US5466823A (en) | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
US5484799A (en) | 1993-12-09 | 1996-01-16 | Abbott Laboratories | Antifungal dorrigocin derivatives |
US5393790A (en) | 1994-02-10 | 1995-02-28 | G.D. Searle & Co. | Substituted spiro compounds for the treatment of inflammation |
WO1995024612A1 (fr) | 1994-03-07 | 1995-09-14 | International Business Machines Corporation | Procede et dispositif d'interpolation rapide de valeurs intermediaires derivees de signaux periodiques dephases et de detection de defauts de corps rotatifs |
US5840918A (en) | 1994-03-15 | 1998-11-24 | Eisai Co., Ltd. | Isoprenyl transferase inhibitors |
RU95104898A (ru) | 1994-03-31 | 1996-12-27 | Бристоль-Мейерз Сквибб Компани (US) | Имидазолсодержащие ингибиторы фарнезид-протеинтрансферазы, способ лечения связанных с ней заболеваний |
US5523430A (en) | 1994-04-14 | 1996-06-04 | Bristol-Myers Squibb Company | Protein farnesyl transferase inhibitors |
US5510510A (en) | 1994-05-10 | 1996-04-23 | Bristol-Meyers Squibb Company | Inhibitors of farnesyl protein transferase |
US5563255A (en) | 1994-05-31 | 1996-10-08 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
AU2742195A (en) | 1994-06-10 | 1996-01-05 | Rhone-Poulenc Rorer S.A. | Novel farnesyl transferase inhibitors, their preparation and pharmaceutical compositions containing same |
US5571792A (en) | 1994-06-30 | 1996-11-05 | Warner-Lambert Company | Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase |
WO1996005529A1 (fr) | 1994-08-09 | 1996-02-22 | Micron Optics, Inc. | Filtres de fabry-perot a fibres compense en temperature |
CA2155448A1 (fr) | 1994-08-11 | 1996-02-12 | Katerina Leftheris | Inhibiteurs de la farnesyl-proteine-transferase |
WO1996005168A1 (fr) | 1994-08-11 | 1996-02-22 | Banyu Pharmaceutical Co., Ltd. | Derive d'amide substitue |
WO1996005169A1 (fr) | 1994-08-12 | 1996-02-22 | Banyu Pharmaceutical Co., Ltd. | Derive d'acide amique n,n-bisubstitue |
DE4429506B4 (de) | 1994-08-19 | 2007-09-13 | Degussa Gmbh | Verfahren zur Extraktion natürlicher Carotinoid-Farbstoffe |
DE4429653C2 (de) | 1994-08-20 | 1997-04-03 | Anton Dr More | Konverter und Verfahren zum Frischen von Metallschmelzen insbesondere von Roheisen zu Stahl |
DE69507284T2 (de) | 1994-11-22 | 1999-07-01 | Philips Electronics Nv | Halbleiter mit einem träger auf dem ein substrat mit einem halbleiter-element mittels einer klebeschicht und ein leiterbahn-muster befestigt sind |
WO1996017861A1 (fr) | 1994-12-09 | 1996-06-13 | Warner-Lambert Company | Tetrapeptide et pentapeptide substitues servant d'inhibiteurs de la proteine:farnesyle transferase |
EP0802953A2 (fr) | 1995-01-09 | 1997-10-29 | Magla International Ltd | Impression d'image resistant a l'usure sur des surfaces en latex |
EP0794789A4 (fr) | 1995-01-12 | 1999-05-26 | Univ Pittsburgh | Inhibiteurs des prenyle transferases |
FR2729390A1 (fr) | 1995-01-18 | 1996-07-19 | Rhone Poulenc Rorer Sa | Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent |
US5633272A (en) | 1995-02-13 | 1997-05-27 | Talley; John J. | Substituted isoxazoles for the treatment of inflammation |
US6020343A (en) | 1995-10-13 | 2000-02-01 | Merck Frosst Canada, Inc. | (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors |
PT873341E (pt) | 1995-11-17 | 2004-02-27 | Biotechnolog Forschung Mbh Gbf | Derivados de epotilona preparacao e utilizacao |
TR199802049T2 (xx) | 1996-04-12 | 1999-01-18 | G.D.Searle & Co. | COX-2 Inhibit�rlerinin �nilac� olarak s�bstit�e edilmi� benzens�lfonamid t�revleri. |
US5861419A (en) | 1996-07-18 | 1999-01-19 | Merck Frosst Canad, Inc. | Substituted pyridines as selective cyclooxygenase-2 inhibitors |
DE69734362T2 (de) | 1996-12-03 | 2006-07-20 | Sloan-Kettering Institute For Cancer Research | Synthese von epothilonen, zwischenprodukte dazu, analoga und verwendungen davon |
KR100666887B1 (ko) | 1997-10-08 | 2007-01-10 | 상꾜 가부시키가이샤 | 치환 축합 복소환 화합물 |
NZ505844A (en) | 1997-12-22 | 2003-10-31 | Bayer Ag | Inhibition of raf kinase using substituted heterocyclic ureas |
JP4169450B2 (ja) | 1999-04-07 | 2008-10-22 | 第一三共株式会社 | インスリン抵抗性改善剤 |
CN1350534A (zh) | 1999-04-12 | 2002-05-22 | 阿文蒂斯药物有限公司 | 作为整联蛋白拮抗剂的取代双环杂芳基化合物 |
ATE323482T1 (de) | 1999-07-02 | 2006-05-15 | Stuart A Lipton | Verwendung von p38 mapk inhibitoren in der behandlung von augenkrankheiten |
WO2002044156A2 (fr) | 2000-11-29 | 2002-06-06 | Glaxo Group Limited | Composes chimiques |
AUPR213700A0 (en) | 2000-12-18 | 2001-01-25 | Biota Scientific Management Pty Ltd | Antiviral agents |
PL367325A1 (en) | 2001-04-16 | 2005-02-21 | Tanabe Seiyaku Co, Ltd. | Large conductance calcium-activated k channel opener |
US7642278B2 (en) | 2001-07-03 | 2010-01-05 | Novartis Vaccines And Diagnostics, Inc. | Indazole benzimidazole compounds |
CA2480638C (fr) | 2002-03-29 | 2013-02-12 | Chiron Corporation | Benzazoles substitues et leur utilisation en tant qu'inhibiteurs de la kinase raf |
US8299108B2 (en) | 2002-03-29 | 2012-10-30 | Novartis Ag | Substituted benzazoles and methods of their use as inhibitors of raf kinase |
US7598258B2 (en) * | 2002-05-01 | 2009-10-06 | Kirin Beer Kabushiki Kaisha | Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of macrophage colony stimulating factor receptor |
US7144888B2 (en) | 2002-08-08 | 2006-12-05 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
CA2504941C (fr) | 2002-11-08 | 2012-06-26 | Neurogen Corporation | 6-arylpyridines substituees en position 3 |
DE10306250A1 (de) | 2003-02-14 | 2004-09-09 | Aventis Pharma Deutschland Gmbh | Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
US7531553B2 (en) | 2003-03-21 | 2009-05-12 | Amgen Inc. | Heterocyclic compounds and methods of use |
SI2213661T1 (sl) * | 2003-09-26 | 2011-11-30 | Exelixis Inc | c-Met modulatorji in postopki uporabe |
DE602004021838D1 (de) | 2003-10-16 | 2009-08-13 | Novartis Vaccines & Diagnostic | Substituierte benzazole und ihre verwendung als raf-kinase-hemmer |
BRPI0418212A (pt) | 2003-12-29 | 2007-04-27 | Banyu Pharma Co Ltd | composto ou um sal deste farmaceuticamente aceitável, ativador da glicocinase, e, medicamentos para a terapia e/ou prevenção da diabete, e da obesidade |
AU2005207946A1 (en) * | 2004-01-23 | 2005-08-11 | Amgen Inc. | Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer |
EP2295427A1 (fr) | 2004-04-30 | 2011-03-16 | Bayer HealthCare, LLC | Derives de pyrazolyl uree substitues utiles dans le traitement du cancer |
MXPA06013250A (es) | 2004-05-14 | 2007-02-28 | Abbott Lab | Inhibidores de quinasa como agentes terapeuticos. |
KR20070038500A (ko) | 2004-06-04 | 2007-04-10 | 아스트라제네카 아베 | erbB 수용체 타이로신 키나제로서의 퀴나졸린 유도체 |
BRPI0510929A (pt) | 2004-06-18 | 2007-07-17 | Chiron Corp | derivados de n-(1-(1-benzil-4-fenil-1h-imidazol-2-il)-2,2-dimetilpropil) benzamida e compostos relacionados como inibidores de proteìna de eixo de kinesin (ksp) para o tratamento de cáncer |
EP2010528B1 (fr) * | 2006-04-19 | 2017-10-04 | Novartis AG | Composés à base de benzoxazole et de benzothiazole 6-0 substitués et procédés d'inhibition de signalisation csf-1r |
-
2007
- 2007-04-18 EP EP07797244.6A patent/EP2010528B1/fr active Active
- 2007-04-18 JP JP2009506754A patent/JP5328640B2/ja active Active
- 2007-04-18 US US11/737,069 patent/US7553854B2/en active Active
- 2007-04-18 SI SI200731995T patent/SI2010528T1/en unknown
- 2007-04-18 SM SM200800063T patent/SMP200800063B/it unknown
- 2007-04-18 MX MX2008013427A patent/MX2008013427A/es active IP Right Grant
- 2007-04-18 BR BRPI0710540-1A patent/BRPI0710540B1/pt active IP Right Grant
- 2007-04-18 HU HUE07797244A patent/HUE035654T2/en unknown
- 2007-04-18 CA CA2649288A patent/CA2649288C/fr active Active
- 2007-04-18 LT LTEP07797244.6T patent/LT2010528T/lt unknown
- 2007-04-18 DK DK07797244.6T patent/DK2010528T3/en active
- 2007-04-18 KR KR1020087028138A patent/KR101464385B1/ko active IP Right Grant
- 2007-04-18 RS RS20171176A patent/RS56600B1/sr unknown
- 2007-04-18 PT PT77972446T patent/PT2010528T/pt unknown
- 2007-04-18 ES ES07797244.6T patent/ES2654847T3/es active Active
- 2007-04-18 WO PCT/US2007/066898 patent/WO2007121484A2/fr active Application Filing
- 2007-04-18 EA EA200802129A patent/EA018917B1/ru not_active IP Right Cessation
- 2007-04-18 PL PL07797244T patent/PL2010528T3/pl unknown
- 2007-04-18 TW TW096113570A patent/TW200813039A/zh unknown
- 2007-04-18 AU AU2007237904A patent/AU2007237904B2/en active Active
- 2007-04-18 PE PE2007000472A patent/PE20080359A1/es not_active Application Discontinuation
- 2007-04-19 AR ARP070101682A patent/AR060545A1/es unknown
-
2008
- 2008-10-07 IL IL194662A patent/IL194662A0/en unknown
- 2008-10-15 CR CR10365A patent/CR10365A/es not_active Application Discontinuation
- 2008-10-17 TN TNP2008000406A patent/TNSN08406A1/en unknown
- 2008-10-17 EC EC2008008830A patent/ECSP088830A/es unknown
- 2008-11-10 MA MA31372A patent/MA30407B1/fr unknown
- 2008-11-13 NO NO20084800A patent/NO20084800L/no not_active Application Discontinuation
-
2009
- 2009-05-08 US US12/387,946 patent/US8173689B2/en active Active
-
2012
- 2012-04-23 US US13/453,202 patent/US8710048B2/en active Active
-
2017
- 2017-12-12 HR HRP20171924TT patent/HRP20171924T1/hr unknown
- 2017-12-15 CY CY20171101315T patent/CY1119679T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA30407B1 (fr) | Composes a base de benzoxazole et de benzothiazole 6-0 substitues et procedes d'inhibition de signalisation csf-1r | |
FR16C0021I2 (fr) | Azetidines en tant qu'inhibiteurs de mek et leur utilisation pour le traitement des maladies proliferatives | |
DE60330187D1 (de) | Fluoralkoxy-substituierte 1, 3-dihydro-isoindolyl-verbindungen und ihre pharmazeutischen verwendungen | |
NO20060328L (no) | Kombinasjon av mGluR2-antagonist og ACHE-inhibitor for behandiing av akutt og/eller kronisk neurologiske forstyrrelser | |
MY140031A (en) | Carbonyl compounds | |
MXPA04002167A (es) | Inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes. | |
NZ548954A (en) | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | |
BR0313059B8 (pt) | composto, e, composição farmacêutica | |
DE60312017D1 (de) | Sulfonderivate zur hemmung von gamma-secretase | |
EA200100937A1 (ru) | Способы и композиции, использующие (-)-норцисаприд в комбинации с ингибиторами протонных насосов или антагонистами h2-рецепторов | |
MX2007003470A (es) | Compuestos de carbonilo los cuales pueden utilizarse como inhibidores del factor de coagulacion xa. | |
MA32070B1 (fr) | Dérivés hétérocycliques réunis par fusion et procédés d'utilisation associés | |
MY144318A (en) | Methods of treating hiv infection. | |
ATE453393T1 (de) | Verwendung von pyridylamiden als angiogenesehemmer | |
BR0308339A (pt) | Indazóis substituìdos com uma atividade anticancerosa | |
UA84453C2 (ru) | Применение производных метиленамида для лечения сердечно-сосудистых заболеваний | |
MA29795B1 (fr) | Inhibiteurs de la dipeptidyl peptidase permetttant de traiter le diabete | |
TW200733976A (en) | Method for the treatment of cognitive dysfunction | |
ATE506959T1 (de) | Verwendung von il-18 inhibitoren | |
AP2004002998A0 (en) | Intraorally disintegrating valdecoxib compositions | |
MXPA05005314A (es) | Compuestos de lapacona novedosos y metodos de uso de los mismos. | |
MX2020010181A (es) | Compuestos de piperidina como inhibidores covalentes de menina. | |
TW200735868A (en) | Compositions and methods for treating CNS disorders | |
WO2004030671A3 (fr) | Utilisation de 4-amino-quinazolines comme agents anticancereux | |
TW200801005A (en) | Acetylenic piperazines as metabotropic glutamate receptor antagonists |